McKesson Corporation MCK
1,079.79 USD -2.80 (-0.26%)
At closeNov 11, 2026, 4:57 PM EST
1,079.79 0.00 0.00%
After hours · Nov 11, 4:57 PM ET
1,067.38 Day range 1,081.38
723.68 52-week range 1,121.50
- YTD
- +31.64%
- 1 year
- +26.08%
News
zacks.com Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
fxempire.com Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs McKesson Corporation (MCK) shares up over 235% since May 2022 thanks to institutional support.
zacks.com 3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK) McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
benzinga.com JP Morgan Maintains Overweight on McKesson, Raises Price Target to $1255 JP Morgan analyst Lisa Gill maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $1042 to $1255.
marketbeat.com McKesson Q2 Earnings Call Highlights McKesson NYSE: MCK raised its fiscal 2027 adjusted earnings outlook after reporting higher second-quarter revenue and profit, supported by prescription volumes, specialty distribution and demand for…
zacks.com McKesson (MCK) Upgraded to Buy: Here's What You Should Know McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com McKesson Corporation (MCK) Hit a 52 Week High, Can the Run Continue? McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
benzinga.com UBS Maintains Buy on McKesson, Raises Price Target to $1250 UBS analyst Kevin Caliendo maintains McKesson (NYSE:MCK) with a Buy and raises the price target from $1200 to $1250.
benzinga.com TD Cowen Maintains Buy on McKesson, Raises Price Target to $1200 TD Cowen analyst Charles Rhyee maintains McKesson (NYSE:MCK) with a Buy and raises the price target from $1006 to $1200.
benzinga.com Leerink Partners Maintains Outperform on McKesson, Raises Price Target to $1200 Leerink Partners analyst Michael Cherny maintains McKesson (NYSE:MCK) with a Outperform and raises the price target from $1070 to $1200.- benzinga.com RBC Capital Maintains Sector Perform on McKesson, Raises Price Target to $965 RBC Capital analyst Ryan Halsted maintains McKesson (NYSE:MCK) with a Sector Perform and raises the price target from $845 to $965.
zacks.com MCK Q2 Earnings Call Highlights Raised Outlook and Specialty Growth McKesson raises its fiscal 2027 earnings outlook after strong Q2 results, fueled by specialty drug demand, operating gains and higher-margin healthcare expansion.
seekingalpha.com Bristol Gate U.S. Equity Q3 2026 Portfolio Review Microsoft was the largest contributor, with its shares up 37.8% for the quarter. KLA and Applied Materials were the largest detractors, falling 35.3% and 29.2%. On a relative basis, three of the…
zacks.com MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised McKesson's Q2 fiscal 2027 earnings beat estimates on specialty growth and higher prescription volumes, prompting raised guidance despite an after-hours stock dip.
benzinga.com Evercore ISI Group Maintains Outperform on McKesson, Raises Price Target to $1200 Evercore ISI Group analyst Elizabeth Anderson maintains McKesson (NYSE:MCK) with a Outperform and raises the price target from $1000 to $1200.
seekingalpha.com McKesson Corporation (MCK) Q2 2027 Earnings Call Transcript McKesson Corporation (MCK) Q2 2027 Earnings Call Transcript
zacks.com Here's What Key Metrics Tell Us About McKesson (MCK) Q2 Earnings The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
zacks.com McKesson (MCK) Beats Q2 Earnings and Revenue Estimates McKesson (MCK) came out with quarterly earnings of $11.68 per share, beating the Zacks Consensus Estimate of $10.69 per share. This compares to earnings of $9.86 per share a year ago.
benzinga.com UPDATE: McKesson Raises FY2027 Adj EPS Guidance from $44.20-$45.00 to $45.60-$46.40 vs $44.71 Est; Raises FY2027 Sales Guidance from $423.601B-$439.739B to $427.636B-$443.773B vs $432.063B Est McKesson (NYSE:MCK) raises FY2027 Adj EPS guidance from $44.20-$45.00 to $45.60-$46.40 vs $44.71 analyst estimate. Raises FY2027 sales outlook from $423.601 billion-$439.739 billion to $427.636…
benzinga.com McKesson Q2 2027 Earnings Call Transcript McKesson (NYSE:MCK) reported second-quarter financial results on Wednesday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by…
businesswire.com McKesson Reports Fiscal 2027 Second Quarter Results and Raises Full Year Adjusted EPS Guidance IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2027 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at…
benzinga.com McKesson Q2 Adj. EPS $11.68 Beats $10.70 Estimate, Sales $110.957B Beat $109.875B Estimate McKesson (NYSE:MCK) reported quarterly earnings of $11.68 per share which beat the analyst consensus estimate of $10.70 by 9.16 percent. This is a 18.46 percent increase over earnings of $9.86 per…
benzinga.com Dow Rallies 2.9%, Oil Sinks 7% After Midterms: Stock Market Today Democrats' sweep of Congress lifted hyperscalers and retailers, sank oil and data-center builders, and pulled yields lower.
zacks.com Why McKesson (MCK) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
zacks.com Wall Street Bulls Look Optimistic About McKesson (MCK): Should You Buy? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often…
zacks.com Will MCK's Pharma & Specialty Demand Offset Pricing Headwind in Q2? McKesson's Q2 earnings outlook hinges on strong prescription volumes, specialty distribution and oncology growth amid branded drug pricing pressures.
seekingalpha.com Conventum - Alluvium Global Fund Q3 2026 Performance Update The Fund was down 3.2% in EUR terms, 3.8% in USD and 4.2% in AUD terms. Once again, for the third consecutive quarter, the most notable highlight for investors is a new position - this time, it is…
defenseworld.net 765 McKesson Corporation $MCK Shares Bought by Choreo LLC Choreo LLC boosted its stake in shares of McKesson Corporation (NYSE: MCK) by 9.5% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
zacks.com Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key Metrics Besides Wall Street's top-and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the…
zacks.com Why McKesson (MCK) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
benzinga.com Here's How Much $100 Invested In McKesson 5 Years Ago Would Be Worth Today McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 25.96% on an annualized basis producing an average annual return of 36.71%. Currently, McKesson has a market capitalization of…- benzinga.com Mizuho Maintains Neutral on McKesson, Raises Price Target to $1020 Mizuho analyst Steven Valiquette maintains McKesson (NYSE:MCK) with a Neutral and raises the price target from $905 to $1020.
- benzinga.com UBS Maintains Buy on McKesson, Raises Price Target to $1200 UBS analyst Kevin Caliendo maintains McKesson (NYSE:MCK) with a Buy and raises the price target from $1080 to $1200.
benzinga.com Jim Cramer: This Health Care Stock Is A ‘Winner’, X-Energy Is ‘Losing Too Much Money’ Cramer favors McKesson and Medtronic, while avoiding X-Energy and Cipher; he says Vishay is overpriced and advises waiting for a dip.
benzinga.com Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.- benzinga.com Leerink Partners Maintains Outperform on McKesson, Raises Price Target to $1070 Leerink Partners analyst Michael Cherny maintains McKesson (NYSE:MCK) with a Outperform and raises the price target from $1030 to $1070.
benzinga.com AMD, Constellation Energy, Marvell Technology, Option Care Health and FuelCell Energy: Why These 5 Stocks Are on Investors' Radars Today AMD, CEG, MRVL, OPCH, FCEL were among the stocks seen trending on Tuesday, Oct. 6, 2026.
benzinga.com Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread Option Care Health agreed to a $5.8B buyout by CD&R and McKesson at $32.05 per share, pending shareholder and regulatory approvals.
benzinga.com McKesson Takes A Stake In Option Care — With An Option On The Rest CD&R and McKesson acquire Option Care Health in a $5.8 billion transaction at $32.05 per share as analysts assess acquisition terms.- benzinga.com CD&R, McKesson Agree To Acquire Option Care Health For $32.05 Per share CD&R, McKesson Corporation (NYSE: MCK) ("McKesson"), and Option Care Health, Inc. (NASDAQ:OPCH) ("Option Care Health") announced today that they have entered into a definitive agreement, under which
benzinga.com Here's How Much $1000 Invested In McKesson 20 Years Ago Would Be Worth Today McKesson (NYSE:MCK) has outperformed the market over the past 20 years by 6.56% on an annualized basis producing an average annual return of 15.64%. Currently, McKesson has a market capitalization of…
benzinga.com Cardinal Health, McKesson Double Down on CVS Deals Through 2032 Cardinal Health and McKesson extend drug distribution deals with CVS Health through June 2032, reaffirming FY2027 adjusted earnings guidance.- benzinga.com McKesson Reiterates FY27 Adjusted EPS Outlook Range Of $44.20 To $45 McKesson Corporation (NYSE: MCK) announced today it is reaffirming its fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00 and its long-term adjusted EPS growth rate of 13% to 16%. Further…
benzinga.com Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 22.21% on an annualized basis producing an average annual return of 34.23%. Currently, McKesson has a market capitalization of…
benzinga.com Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 23.05% on an annualized basis producing an average annual return of 34.83%. Currently, McKesson has a market capitalization of…- benzinga.com RBC Capital Reiterates Sector Perform on McKesson, Maintains $845 Price Target RBC Capital analyst Ryan Halsted reiterates McKesson (NYSE:MCK) with a Sector Perform and maintains $845 price target.
benzinga.com A Congress Member Sold Up To $15K In Viasat Stock: Here's What You Need To Know A September filing shows that Representative Jonathan Jackson reported a sale in Viasat (NASDAQ:VSAT), valued between $1,001 and $15,000. The transaction date is listed as August 28, 2026, with the…- benzinga.com Here’s How Much You Would Have Made Owning McKesson Stock In The Last 10 Years McKesson (NYSE:MCK) has outperformed the market over the past 10 years by 3.54% on an annualized basis producing an average annual return of 17.04%. Currently, McKesson has a market capitalization of…
benzinga.com McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization McKesson will acquire Precision Medicine Group for $2.25 billion, expanding its clinical research and drug commercialization services.